BRIEF-Biofrontera Inc. Announces Last-Patient-Out In Phase 2B Study Of Ameluz® (Aminolevulinic Acid HCI) Topical Gel
Reuters
Aug 25, 2025
BRIEF-Biofrontera Inc. Announces Last-Patient-Out In Phase 2B Study Of Ameluz® (Aminolevulinic Acid HCI) Topical Gel
Aug 25 (Reuters) - Biofrontera Inc BFRI.O:
BIOFRONTERA INC. ANNOUNCES LAST-PATIENT-OUT IN PHASE 2B STUDY OF AMELUZ® (AMINOLEVULINIC ACID HCI) TOPICAL GEL, 10% FOR THE TREATMENT OF MODERATE TO SEVERE ACNE VULGARIS
BIOFRONTERA INC - FDA DISCUSSION PLANNED Q3 2026 FOR PHASE 3 PROGRAM
Source text: ID:nGNX31pqSK
Further company coverage: BFRI.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.